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achieved. The mean PA pressure was reduced >20 mmHg to
<25 mmHg. Though reperfusion pulmonary injury developed
in 60% patients after BPA, only 6% patients (as compared to
17% in a previous study) required mechanical ventilatory
support. I/V epoprostenol, methylprednisolone and NIPPV
have all been tried to reduce it, but all have failed to do so. An
attempt has been made, however, to reduce this complica-
tion by not dilating >2 vessels at the initial BPA and perform
it in a staged fashion over multiple, separate procedures and
also by doing limited BPA only within a single lobe at a time.
The reduction in this complication with time also indicates a
role for learning curve and proficiency of operators per-
forming BPA.
Considering the fact that reperfusion injury is unavoidable
despite best efforts, postprocedural intensive monitoring of
hemodynamics and oxygenation at least for 72 h is necessary,
even if the patient appears to be free from pulmonary injury
after BPA.
In my opinion, refined BPA using the technique as in this
study, can be used to remove stenosis in distal pulmonary
arteries to obtain a substantial decrease in PA pressure and
to improve WHO functional class in patients who are not
candidates for either endarterectomy or lung trans-
plantation. It is not that complicated procedure and it can be
done by interventional cardiologist doing coronary inter-
vention. However, there is definitely a learning curve and
acquiring BPA technique and training is necessary, which is
the case as with any procedure. Though the numbers in this
study are small (68 patients) and follow-up was for 2.2  1.4
years only, it has offered a ray of hope to inoperable patients
and further larger studies with longer follow-up and
randomized trials versus medical therapy is the need of the
hour for such patients.
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Rate control is often the therapy of choice for permanent
atrial fibrillation. The RACE II study was the first to evaluate
the relative efficacy of strict rate control (resting heart
rate< 80 bpmand duringmoderate exercise<110 bpm) versus
lenient rate control (resting heart rate <110 bpm) in patients
with permanent AF. The study demonstrated that lenient rate
control was not only easier to achieve but was non-inferior to
strict rate control in reducing symptoms, improving thequality of life, exercise tolerance and survival. However, an
important limitation was the marked discrepancy in the
number of patients achieving target heart rate (THR), in the
two groups. While only 67% achieved THR in the strict rate
control group, almost all (98%) achieved THR in the lenient
rate control group.
Since this could have influenced the outcome in favor of
lenient rate control, the present post hoc analysis evaluated
differences in outcomes in patients with successful strict
(n¼ 203), failed strict (n¼ 98), and lenient rate control (n¼ 307).
Patients in the strict rate control group who failed to achieve
one of the heart rate criteria were classified as failed strict
while the remaining patients were classified as successful
strict rate control.
Nearly 80% of patients in the failed strict group had resting
heart rate >80 bpm at the end of dose-adjustment phase.
Reasons for failure to achieve strict rate control included drug-
related adverse events in 25% and inability to achieve THR
with drugs in another 20% patients.
Clinical characteristics and echocardiographic parameters
(including left atrial and left ventricular dimensions and
baseline EF) were similar amongst the three groups. Mean
dosages of rate control drugs (beta blockers, verapamil and
digoxin) as well as use of drug combination was significantly
higher in successful strict and failed rate control as compared
to lenient rate control groups. The number of additional hos-
pital visits at 1 and 2 years of follow upwere significantlymore
common in the successful strict and failed strict compared
with the lenient group while there was no difference in
additional visits between the successful strict and failed strict
groups.
The primary outcome (composite of death from car-
diovascular causes, hospitalization for heart failure, and
stroke, systemic embolism, bleeding, and life-threatening
arrhythmic events), all-cause mortality and quality of life
scores were not significantly different amongst patients with
strict, failed strict or lenient rate control. Separate analysis of
patients with EF <40% also revealed no differences in the
primary outcome. Whether use of more aggressive measures
to achieve strict rate control or longer follow up would reveal
any outcome differences remains to be studied further.
The study confirms that it is often difficult to achieve strict
heart rate control in patients with AF with currently available
anti-arrhythmic drugs. Not only do these patients require
higher dosages of drugs and drug combinations, but the
number of additional hospital visits is also more. Despite
achieving pre-specified target heart rate, there was no differ-
ence in outcome between successful and failed strict rate
control. Therefore a strategy of lenient rate control may con-
tinue to be the preferred strategy in patients with permanent
AF. However in patients with intolerable rate related symp-
toms or onset of tachycardiomyopathy, lower heart rate tar-
gets may be reasonable.
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i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 3 4 7e3 5 2 351Prognostic Impact of the Presence and Absence of Angina onMortality and Cardiovascular Outcomes in Patients With
Type 2 Diabetes and Stable Coronary Artery Disease. Results
from the BARI 2D (Bypass Angioplasty Revascularization
Investigation 2 Diabetes) Trial
Objectives: The purpose of this analysis was to assess in
patients with type 2 diabetes and stable coronary artery dis-
ease, (CAD) whether the risk of all-cause mortality and car-
diovascular events varied according to the presence or
absence, of angina and angina equivalent symptoms.
Background: Data on the prognostic value of symptoms in
these patients are limited. Methods Post-hoc analysis was
performed in 2,364 patients with type 2 diabetes and docu-
mented CAD enrolled in the, BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) trial to determine
the occurrence of, death and composite of death, myocardial
infarction, and stroke during a 5-year follow-up according to
cardiac symptoms at baseline.
Results:Therewere 1,434 patientswith angina (A), 506with
angina equivalents (E), and 424 with neither of these (N). The
cumulative death rates (total 316) were 12% in A, 14% in E, and
10% in N (p 0.3), and cardiovascular composite rates (total 548)
were 24% in A, 24% in E, and 21% in N (p 0.5). ComparedwithN,
the hazard ratios adjusted for confounders were not different
for death in A (1.11; 99%CI: 0.81 to 1.53) and E (1.17; 99%CI: 0.81
to 1.68) or for cardiovascular events in A (1.17; 99% CI: 0.92 to
1.50) and E (1.11; 99% CI: 0.84 to 1.48).
Conclusions: Whatever their symptom status, patients
with type 2 diabetes and stable CAD were at similar risk of
cardiovascular events and death. These findings suggest that
these patients may be similarly managed in terms of risk
stratification and preventive therapies. (Bypass Angioplasty
Revascularization Investigation 2 Diabetes [BARI 2D];
NCT00006305) (J AmColl Cardiol 2013;61:702e11)ª 2013 by the
American College of Cardiology Foundation
Diabetes mellitus (DM) is a global epidemic. Accelerated
atherosclerosis inDMleads tohigh incidenceofCardiovascular
Disease (CVD). Coronary Artery Disease (CAD) accounts for
large fraction of morbidity, mortality and cost of DM.
In Bypass Angioplasty Revascularization Investigation 2
Diabetes (BARI 2D) trial, it was analyzed whether symptoms
affect prognosis or not in Type 2 DM and CAD with docu-
mented ischemia.
A total of 2368 patientswith Type 2DMand stable CADwith
documented ischemia were followed up for 5.3 years. Patients
were divided into those with angina, angina equivalent
(dyspnea, palpitation or diaphoresis on exertion) or no cardiac
symptom.
Stable CAD and Type 2DM had similar long term prognosis
across a variety of cardiovascular outcome irrespective of
their symptomatic status. Five-year death rate was 12% with
angina, 14%with angina equivalent, and 10% in asymptomatic
patient. Cumulative 5-year composite outcome rate were 24%,
24% and 21%, respectively. Asymptomatic patients were at the
same relative high risk for all cause mortality, the composite
outcome, CVD death, nonfatal myocardial infarction (MI) and
nonfatal stroke, compared to patients with angina or anginaequivalent. These were independent of baseline character-
istics, severity of CAD and coronary revascularization. In
separate analysis of optimized medical therapy and revascu-
larization, the outcome remained unchanged. Left ventricular
systolic function was normal in all three groups. Exercise
induced ischemia causing diastolic dysfunction could be
responsible for exertional dyspnea qualifying angina
equivalent.
Summarizing, the take home message of this study is that
Type 2DM, stable CAD with documented ischemia and no
symptoms are at the same high risk for all causemortality and
major cardiovascular outcomes compared to those with
angina or angina equivalent. These patients should be sim-
ilarly managed in terms of risk stratification and preventive
therapy.
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years of age. Circulation 2013;127:585e593.Objectives: The purpose of this study was to describe the
clinical courseand risk stratifyolderpatientswithhypertrophic
cardiomyopathy (HCM) who were more than 60 years of age.
Background: Twomajor problems associatedwith HCM are
risk for sudden death and disease progression. These are rel-
atively well defined in young patients. Whether patients of
moreadvancedageharborsimilar risks isunresolvedandoften
creates clinical dilemmas, particularly in decisions for primary
prevention of sudden death with implantable defibrillators.
Methods: Patients for this study were selected from data-
bases of 2 large HCM centers in USA. Consecutively presenting
patients with HCM, who were 60 years of age at first pre-
sentation to these centers were selected for this study. These
patientswere followedupbyhospital visit or telephonecontact.
Results: 428 consecutive older HCM patients were followed
for 5.8 4.8 years. Of these, 279 (65%) survived to 73 7 years of
age, most with no/mild symptoms including 135 with 1 con-
ventional sudden death risk factors and 50 (37%) with late
gadoliniumenhancement.Onfollow-up,149 (35%)diedat808
years of age, mostly from non-HCM related causes (n ¼ 133,
31%), including a substantial proportion from non-cardiac dis-
ease (n¼ 54). Sixteen patients (3.7%) had HCM relatedmortality
events (0.64%/year), including embolic stroke (n ¼ 6), pro-
gressive heart failure or transplantation (n ¼ 3), postoperative
complications (n ¼ 2), and arrhythmic sudden death events
(n ¼ 5, 1.2% [0.20%/year]). All-cause mortality was increased in
HCM patients60 years of age comparedwith an age-matched
US general population, predominantly as a result of non-HCM
related diseases (p < 0.001; standardmortality ratio, 1.5).
Conclusions: HCM patients surviving into the seventh
decade of life are at low risk for disease-related morbidity,
mortality and sudden death, even in presence of conventional
